Neurodegenerative diseases affect tens of millions of people worldwide. Among these, Alzheimer’s and Parkinson’s diseases are the most common; in the United States alone, the Alzheimer’s Disease Association and Parkinson’s Foundation report roughly 7 million people with Alzheimer’s and another million with Parkinson’s. An intriguing clue lies in the tangled mystery of neurodegeneration that scientists are working to solve: iron accumulation.

Scientists have noticed that iron can slowly build up inside neurons. Early in life, this iron accumulation appears to have little effect on neuronal function. However, later in life, it can contribute to a slow neuronal demise. Salk Institute researchers studied nerve cells to figure out whether and how this iron accumulation relates to neurodegenerative diseases. They found that the excess iron stuck in neurons lowers the cells’ defenses, making them more vulnerable to stressors and other cellular insults through a process they named chronoferroptosis.

The study, published in Cell Death Discovery on June 18, 2026, points to iron accumulation as a key target in the effort to predict, prevent and treat neurodegenerative diseases.

The synaptic homeostasis hypothesis posits that sleep is essential for restoring cerebral equilibrium by downscaling synaptic connections that progressively strengthen and accumulate metabolic costs during wakefulness. While previously supported only by preclinical animal models, a recent study provides direct in vivo evidence of this mechanism in humans. Researchers evaluated 40 volunteers, half of whom underwent 28 hours of continuous sleep deprivation, utilizing Positron Emission Tomography (PET) to quantify levels of the SV2A protein, a reliable biomarker for synaptic density. The findings revealed that prolonged wakefulness significantly elevated SV2A levels across multiple brain regions, most notably in the hippocampus and thalamus. Furthermore, during a subsequent two-hour recovery sleep period, these elevated SV2A levels were strongly correlated with enhanced slow-wave activity, a primary electrophysiological marker of deep sleep and homeostatic sleep pressure. These results validate the synaptic homeostasis hypothesis in humans, demonstrating a measurable biological link between sleep deprivation, the accumulation of neural connections, and the restorative drive for deep, slow-wave sleep.

---

The synaptic homeostasis hypothesis (SHY) [1– 4] posits that wakefulness promotes synaptic potentiation due to environmental interactions and learning [5]. The strengthening of connections during waking elevates energy consumption, results in the accumulation of proteins and receptors that compete for the limited anatomical space in the skull and diminishes the signal-to-noise ratios in the neuronal network, ultimately saturating the capacity for learning. Sleep allows for synaptic down-selection, preserving energy and network efficiency. While the SHY has been supported by anatomical and molecular studies in animals, human evidence has remained limited due to the invasive nature of most techniques for quantifying synaptic strength.

Studies in animals indicate that anatomical or molecular markers of synaptic strength increase during wake and decline during sleep [6]. Firing rates in rodents indicate increased cortical excitability during wakefulness and decreased cortical excitability during sleep. In humans, cortical excitability is an indirect measure of plasticity. Findings from studies using transcranial magnetic stimulation (TMS) translated the findings from the above-mentioned rodent studies (reviewed in [7]). However, some in-vitro and in-vivo studies of synaptic strength in animals reveal opposite results, which may be due to differences in the type of marker, examined brain regions, cortical layers, or housing of animals (reviewed in [8]).

Synaptic vesicle glycoprotein 2A (SV2A) [9] is an integral membrane protein located on synaptic vesicles. Recent advances in PET imaging with tracers such as [¹⁸F]SynVesT-1 enable the noninvasive measurement of SV2A binding in the living human brain [10,11], allowing new opportunities to examine state-dependent synaptic changes. However, whether this reflects presynaptic terminal number, vesicle complement, SV2A expression per vesicle, or excitatory/inhibitory-synapse composition cannot be resolved with in vivo imaging. While SV2A availability is commonly interpreted as a proxy measure of synaptic density, we refer to it here as ‘SV2A-indexed synaptic density’ to reflect this interpretation while acknowledging its underlying biological ambiguity.

From Vishal Choudhari, PhD, and the lab of Nima Mesgarani, PhD, at Columbia University’s Zuckerman Institute: A new tech monitors the brain to detect who you are listening to. It then amplifies that voice and quiets other voices nearby. Brain surgery patients recently tested the system in hospitals. They heard two overlapping conversations, one on each side. The volunteers then tried to focus on only one conversation. One video here shows a man listening to the overlapping conversations. Researchers ask him to focus on the conversation on his right. Controlled by his brain activity, the system adjusts the volume. In another experiment, he again focuses his attention on the right. The system notices, amplifying a conversation about bread. Then, researchers ask him to switch to the left conversation. The mind reading system turns about another conversation, about repairs. In a different experience, a volunteer can freely choose what to listen to. He starts on the right. A graph appears, showing the system monitoring his brain activity. What happens when he switches from right to left? The system spots his shift in attention and adjusts the volume. Scientists asked volunteers about the experience. “In the second section, what I was listening to was louder, and the other thing was quieter. And in the first section, they were both equally loud. That’s super dope.” “I think if you could really implement it in the hearing aids, if this is the goal, I think it would be really helpful to just be able to have someone who is hard of hearing be able to kind of pinpoint exactly the conversation they want to have, especially if you’re in a location with a lot of people.” “Well I just keep thinking about about Uncle Aaron. Can you imagine if this technology existed in a world that he could access it? He might actually live a much more peaceful… life.”

“Peacemaker” immune cells could help treat diseases ranging from type 1 diabetes to neurodegeneration by restoring immune tolerance, according to a new paper in Frontiers in Science.

From cancer, diabetes and chronic infections to cardiovascular, neurodegenerative and reproductive conditions, inflammation is increasingly cited as a driver of a broad range of diseases. Immune cells called regulatory T cells (Tregs)—originally defined as “suppressor” cells that stop other immune cells from attacking the body—are being explored as “living drugs” that could eventually be adapted to target many diseases with an inflammatory component.

Such an approach, which aims to tailor Treg therapies to specific diseases and tissues, could support more precise control of immune responses. In autoimmune diseases and transplant rejection, Tregs could even help shift treatment from broad immunosuppression, which brings myriad risks, toward restored immune tolerance and longer-term disease control.

Disclaimer: Do NOT attempt without proper medical supervision.

In a paradigm-shifting breakthrough, Phase III clinical trials of DT120 — a novel, pharmaceutical-grade formulation of LSD — have demonstrated unprecedented efficacy in treating Major Depressive Disorder (MDD) following just a single dose. The study, encompassing 149 patients, revealed that a one-time administration of DT120 significantly outperformed a placebo, achieving the trial’s primary endpoint by reducing MADRS depression scores by an 8-point margin at six weeks. Remarkably, patients experienced rapid therapeutic relief within just one week, showcasing a massive 14-point advantage over the placebo group. Unlike conventional daily antidepressants that often take weeks to manifest effects, DT120 delivers profound and sustained symptom reduction from a single intervention. Hailed by Definium Therapeutics’ CEO Rob Burrow as a potential “best-in-class” therapy, these groundbreaking findings not only pave the way for expedited regulatory approval but also underscore the transformative potential of psychedelics to fundamentally revolutionize modern mental health care.

---

Definium Therapeutics has announced strong results in a phase 3 trial of its single-dosed lysergide (LSD) drug DT120 in treating adults with major depressive disorder (MDD), meeting its primary goal and all key secondary efficacy endpoints in the first trial of its kind.

The results come from the Emerge trial, a randomized, double-blind, placebo-controlled study featuring 149 participants aged 18 to 74 years enrolled across 20 sites. The participants all met specific MDD measures. They needed to have a DSM-5-confirmed diagnosis of MDD, a Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 26 and a Clinical Global Impression–Severity (CGI-S) score of at least 4 at screening and baseline.

The study examined the effectiveness of a single 100 µg dose of DT120 ODT compared with a placebo in alleviating MDD symptoms. In 2023, we covered an earlier trial of lysergide, which had shown positive results in treating general anxiety disorder (GAD).

Hundreds of genes have been linked to autism, yet the precise molecular and cellular mechanisms behind it remain largely unclear. A new study published in Nature, led by Gaia Novarino at the Institute of Science and Technology Austria (ISTA), aims to uncover these mechanisms-and in doing so, might lay the groundwork for developing medical therapies.

Autism spectrum conditions, often abbreviated as ASD in scientific and medical literature, are, for example, neurodevelopmental disorders such as epilepsy or intellectual disability. The underlying changes begin during early brain development, while the first signs often become apparent in early childhood and can persist throughout life.